tbResList Print — M-Blu Methylene blue

Filters: qv=12, qv2=%, rfv=%

Product

M-Blu Methylene blue
Description: <b>Methylene blue (MB)</b>, also known as methylthioninium chloride, is a thiazine dye that can be used as a medication, and can be administered orally, subcutaneously(not typical) or intravenously.<br>
Mainly used to treat methemoglobinemia by chemically reducing the ferric iron in hemoglobin to ferrous iron<br>
Methylene blue is commonly used in medical practice, especially as a dye in microbiological staining<br>
Antidote in cyanide poisoning: an oxidation-reduction indicator: an antiseptic<br>
<br>
Pathways:<br>
- may increases the oxygen consumption of normal tissues having aerobic glycolysis, and of tumors<br>
- generate reactive oxygen species (ROS) upon light activation<br>
-effects on mitochondrial metabolism may contribute to modulation of apoptosis and energy metabolism in cancer cells.<br>
-can affect the generation of reactive oxygen species.<br>
-Historically, it was used in patients with urinary tract infection <br>
-MB has also been used as a tracer for cancer diagnosis and as a photosensitizer for cancer treatment <br>
-shifts redox balance and can promote OXPHOS over glycolysis in some models(reverse Warburg effect)<br>
-can cross BBB and reach brain at concentrations 10 times higher than that in the circulation<br>
-causes shift from shift from glycolysis to oxidative phosphorylation.<br>
-reduces glutathione reductase GSR (an enzyme of glutathione metabolism), context- and concentration-dependent
<br>
<br>
<p><b>Methylene blue</b> — Methylene blue (MB), also called methylthioninium chloride, is a synthetic phenothiazine/thiazine redox dye and oxidation–reduction drug with reversible cycling between oxidized methylene blue and reduced leucomethylene blue. It is formally a small-molecule redox-active drug, diagnostic dye, and photosensitizer. Standard abbreviations are MB and, for methylthioninium, MT. Clinically, intravenous methylene blue is an approved treatment for acquired methemoglobinemia; its anticancer applications are investigational. Its unusually broad pharmacology derives from mitochondrial electron transfer, redox cycling, MAO-A inhibition, protein interactions, and strong visible-light absorption that permits photodynamic ROS generation.</p>

<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Alternative mitochondrial electron transfer: accepts electrons from NADH and can transfer them downstream toward cytochrome c, modifying respiratory-chain electron flow and oxygen consumption.</li>
<li>Metabolic reprogramming: in susceptible cancer models, mitochondrial respiration and OXPHOS increase while aerobic glycolysis and lactate production decrease.</li>
<li>Redox cycling and ROS modulation: low concentrations can facilitate electron transfer and limit electron leakage, whereas higher or context-specific exposures can become pro-oxidant.</li>
<li>Light-activated photodynamic activity: photoexcited MB generates singlet oxygen and other ROS, producing strong localized oxidative cytotoxicity.</li>
<li>Mitochondrial stress and intrinsic apoptosis at cytotoxic concentrations, including loss of mitochondrial membrane potential and downstream caspase/PARP-associated cell death.</li>
<li>HSP70 inhibition and disruption of chaperone-dependent survival signaling in selected cancer models.</li>
<li>AMPK activation with downstream ACC inhibition, cyclin suppression, and cell-cycle arrest in metabolically responsive tumor models.</li>
<li>Potent reversible MAO-A inhibition, primarily important as clinically relevant off-target pharmacology and a drug-interaction mechanism.</li>
</ol>

<p><b>Bioavailability / PK relevance:</b> MB distributes extensively into tissues and blood cells. Oral aqueous MB has shown substantial systemic bioavailability, although formulation strongly influences absorption and distribution. The current intravenous label reports a large apparent volume of distribution, approximately 94% plasma protein binding in vitro, and an approximately 24-hour terminal half-life. After 2 mg/kg IV, mean plasma Cmax is approximately 2.9 µg/mL, corresponding to roughly 9 µM. Renal impairment substantially increases systemic exposure. MB crosses the blood–brain barrier, but claims of a fixed brain-to-plasma enrichment ratio should be regarded as model-dependent rather than a universal human PK value.</p>

<p><b>In-vitro vs systemic exposure relevance:</b> Not all anticancer experiments require pharmacologically impossible concentrations. Low-micromolar mitochondrial/metabolic effects can overlap transient concentrations obtained after clinical IV administration. However, experiments using higher micromolar concentrations, prolonged exposure, or direct/local MB administration cannot automatically be extrapolated to safe systemic dosing. Photodynamic and sonodynamic studies are particularly exposure-geometry dependent because cytotoxicity depends on local MB concentration plus light or ultrasound energy rather than systemic concentration alone.</p>

<p><b>Clinical evidence status:</b> <b>Established clinical drug for acquired methemoglobinemia; anticancer evidence is predominantly preclinical.</b> Systemic antitumor use has not been established by cancer RCTs. Small human studies have investigated MB-mediated photodynamic treatment, including basal-cell carcinoma, while cancer-supportive applications such as oral-mucositis pain have progressed to randomized trials. MB is not an approved systemic anticancer therapy. Alzheimer’s/neurodegenerative investigation has reached human randomized studies but has not established methylene blue as standard AD therapy.</p>

<p><b>Safety / translation constraints:</b> Clinically important constraints include potent MAO-A inhibition and potentially serious or fatal serotonin syndrome with serotonergic drugs and opioids. G6PD deficiency is a contraindication because of hemolytic-anemia risk. High doses can themselves promote methemoglobinemia or hemolysis. Renal dysfunction increases exposure. MB also interferes with pulse oximetry and some laboratory measurements. These constraints materially limit extrapolation from high-dose anticancer experiments.</p>




<h3>Methylene Blue Cancer Mechanisms</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>Mitochondrial electron transfer and respiration</td>
<td>OCR ↑; mitochondrial electron flux ↑ (model-dependent)</td>
<td>Respiratory efficiency ↑ at low concentration</td>
<td>P, R</td>
<td>Bioenergetic reprogramming</td>
<td>MB can reversibly cycle between oxidized and reduced states and bypass portions of conventional electron transfer by receiving electrons from NADH and transferring them downstream.</td>
</tr>
<tr>
<td>2</td>
<td>Warburg metabolism and glycolysis</td>
<td>Glycolysis ↓; lactate production ↓; OXPHOS ↑</td>
<td>Variable; metabolic respiration may ↑</td>
<td>R</td>
<td>Reduced glycolytic dependence</td>
<td>Best demonstrated in glioblastoma and related experimental models. Metabolic effects are not universal across tumor types.</td>
</tr>
<tr>
<td>3</td>
<td>Redox cycling and oxidative stress</td>
<td>ROS ↑ at cytotoxic exposure; ROS may ↓ at low exposure (dose-dependent)</td>
<td>ROS ↓ at low concentrations (context-dependent)</td>
<td>P, R</td>
<td>Biphasic redox modulation</td>
<td>MB is not simply an antioxidant or pro-oxidant. Direction depends strongly on concentration, cellular redox state, oxygen availability, and external activation.</td>
</tr>
<tr>
<td>4</td>
<td>Photodynamic ROS generation</td>
<td>ROS ↑↑; singlet oxygen ↑; viability ↓ (requires external trigger)</td>
<td>Local oxidative injury ↑ if illuminated</td>
<td>P</td>
<td>Photoactivated cytotoxicity</td>
<td>A major mechanistically distinct anticancer application. Requires appropriate MB localization, oxygen, wavelength, fluence, and tissue light penetration.</td>
</tr>
<tr>
<td>5</td>
<td>Mitochondrial membrane integrity and apoptosis</td>
<td>Mitochondrial membrane potential ↓; cytochrome-c release ↑; caspase activity ↑; apoptosis ↑</td>
<td>↔ or protected at low dose; toxicity ↑ at high dose</td>
<td>R, G</td>
<td>Intrinsic apoptotic signaling</td>
<td>Particularly prominent during MB-mediated photodynamic or high-concentration exposure.</td>
</tr>
<tr>
<td>6</td>
<td>AMPK and ACC metabolic signaling</td>
<td>AMPK ↑; ACC activity ↓; cyclins ↓</td>
<td>Context-dependent</td>
<td>R, G</td>
<td>Metabolic checkpoint activation</td>
<td>Supports S-phase arrest and reduced proliferation in glioblastoma models; systemic xenograft translation has been inconsistent.</td>
</tr>
<tr>
<td>7</td>
<td>Cell-cycle progression</td>
<td>S-phase arrest ↑; cyclin expression ↓; proliferation ↓</td>
<td>Limited evidence</td>
<td>G</td>
<td>Growth arrest</td>
<td>Primarily linked to metabolic stress and AMPK signaling rather than a universal direct cell-cycle target.</td>
</tr>
<tr>
<td>8</td>
<td>HSP70 chaperone activity</td>
<td>HSP70 activity ↓; survival signaling ↓</td>
<td>HSP70 activity ↓ (context-dependent)</td>
<td>R, G</td>
<td>Proteostasis disruption</td>
<td>Experimentally supported but secondary to the broader mitochondrial/redox pharmacology of MB.</td>
</tr>
<tr>
<td>9</td>
<td>Glutathione redox system</td>
<td>GSR activity ↓ or redox buffering altered (model-dependent)</td>
<td>Variable</td>
<td>R</td>
<td>Redox-buffer modification</td>
<td>Not sufficiently consistent to treat GSH depletion or GSR inhibition as a universal primary MB mechanism.</td>
</tr>
<tr>
<td>10</td>
<td>Chemosensitization</td>
<td>Drug cytotoxicity ↑ in selected combinations</td>
<td>Not established</td>
<td>G</td>
<td>Combination enhancement</td>
<td>Preclinical work includes carboplatin and doxorubicin combinations. MB-PDT can add oxidative stress, but general chemosensitization should not be assumed across drugs.</td>
</tr>
<tr>
<td>11</td>
<td>Monoamine oxidase A</td>
<td>MAO-A ↓</td>
<td>MAO-A ↓↓</td>
<td>P, R</td>
<td>Off-target pharmacology</td>
<td>Clinically important primarily because it creates a substantial serotonin-syndrome interaction risk rather than as an established anticancer mechanism.</td>
</tr>
<tr>
<td>12</td>
<td>Clinical Translation Constraint</td>
<td>Antitumor systemic efficacy not established</td>
<td>Serotonin toxicity and hemolysis risk</td>
<td>—</td>
<td>Translation limitation</td>
<td>Exposure, tumor penetration, biphasic redox behavior, G6PD status, renal function, drug interactions, and light geometry for PDT substantially constrain translation.</td>
</tr>
</table>
<p>P: 0–30 min&nbsp;&nbsp;&nbsp; R: 30 min–3 hr&nbsp;&nbsp;&nbsp; G: &gt;3 hr</p>




<br><br>
<hr>
<br><br>


<p><b>Alzheimer’s disease relevance:</b> Methylene blue has substantial mechanistic relevance to Alzheimer’s disease because it crosses the blood–brain barrier, can function as an alternative mitochondrial electron carrier, modifies oxidative stress, and directly alters tau aggregation. Methylthioninium was evaluated in a randomized Phase II trial in mild-to-moderate AD. A 138 mg/day group generated efficacy signals in prespecified/subgroup analyses, but the study did not establish robust overall efficacy, and subsequent development shifted largely to reduced methylthioninium derivatives such as LMTM. Mechanistic studies also indicate that inhibition of mature tau fibrils does not necessarily eliminate potentially toxic granular tau oligomers. MB therefore has meaningful AD research relevance but should not be classified as clinically established AD therapy.</p>




<h3>Methylene Blue in Alzheimer’s Disease</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Modulation</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>Mitochondrial electron transfer</td>
<td>Electron transfer ↑; complex IV activity ↑; respiration ↑</td>
<td>P, R</td>
<td>Bioenergetic support</td>
<td>Potentially bypasses dysfunctional portions of the respiratory chain and reduces electron leakage at low concentration.</td>
</tr>
<tr>
<td>2</td>
<td>Tau aggregation</td>
<td>Tau fibril formation ↓</td>
<td>G</td>
<td>Protein aggregation modulation</td>
<td>Direct tau-aggregation inhibition is well established experimentally, but effects on toxic oligomer species are more complex.</td>
</tr>
<tr>
<td>3</td>
<td>Tau oligomer balance</td>
<td>Granular tau oligomers ↔ or ↑ (model-dependent)</td>
<td>G</td>
<td>Potential mechanistic limitation</td>
<td>Some work suggests inhibition of fibrils without corresponding elimination of granular oligomers, which may help explain limited clinical efficacy.</td>
</tr>
<tr>
<td>4</td>
<td>Mitochondrial oxidative stress</td>
<td>ROS ↓ at low concentrations</td>
<td>P, R</td>
<td>Neuroprotection</td>
<td>Hormetic response; higher concentrations can become pro-oxidant.</td>
</tr>
<tr>
<td>5</td>
<td>Neuronal energy metabolism</td>
<td>Oxygen consumption ↑; metabolic efficiency ↑</td>
<td>R</td>
<td>Metabolic support</td>
<td>Preclinical evidence is substantially stronger than evidence for disease modification in humans.</td>
</tr>
<tr>
<td>6</td>
<td>Cognition and memory</td>
<td>Memory performance ↑ (preclinical and limited human evidence)</td>
<td>G</td>
<td>Functional outcome</td>
<td>Does not establish efficacy for Alzheimer’s disease progression.</td>
</tr>
<tr>
<td>7</td>
<td>Clinical Translation Constraint</td>
<td>Clinical efficacy uncertain</td>
<td>—</td>
<td>Translation limitation</td>
<td>Phase II signals were not sufficient to establish MB as AD therapy; formulation, dose, tau species, concomitant therapy, and MAO-A-mediated drug interactions remain relevant.</td>
</tr>
</table>
<p>P: 0–30 min&nbsp;&nbsp;&nbsp; R: 30 min–3 hr&nbsp;&nbsp;&nbsp; G: &gt;3 hr</p>






















Pathway results for Effect on Cancer / Diseased Cells

Redox & Oxidative Stress(tgid=1) ⓘ

ROS↑, 6,   ROS⇅, 1,   SOD↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

mtDam↑, 1,   OCR↑, 4,   mt-OXPHOS↑, 1,   OXPHOS↑, 3,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACC↓, 1,   AMPK↑, 2,   ATP↓, 1,   ECAR↓, 1,   GlucoseCon↑, 1,   GlutaM↓, 1,   Glycolysis↓, 3,   lactateProd↓, 3,   NADPH↓, 1,   Warburg↓, 3,  

Cell Death(tgid=5) ⓘ

Bcl-2↓, 1,   Cyt‑c↝, 1,   Mcl-1↓, 1,   TumCD↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

p‑MAPK↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↓, 1,   tumCV↓, 3,  

Protein Folding & ER Stress(tgid=8) ⓘ

HSP70/HSPA5↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

Cyc↓, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

TumCG↓, 2,   TumCP↓, 3,  

Barriers & Transport(tgid=15) ⓘ

MMP↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↝, 2,   Dose?, 1,   eff↓, 1,   eff↑, 1,   Half-Life↝, 1,   selectivity↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

LDH↓, 1,   LDH↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   AntiTum↑, 1,   Mucositis↓, 1,   neuroP↑, 2,   Pain↓, 1,  
Total Targets: 44

Pathway results for Effect on Normal Cells

Redox & Oxidative Stress(tgid=1) ⓘ

mt-antiOx↑, 1,   antiOx↑, 3,   GSR↓, 1,   H2O2↑, 1,   lipid-P↓, 1,   RNS↓, 1,   ROS↓, 5,   SOD↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

compI↑, 2,   compII↑, 1,   compIII↑, 1,   compIV↑, 3,   compV↑, 1,   ETC↝, 1,   ETC↑, 3,   mitResp↑, 1,   OCR↑, 4,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ATP↑, 2,   ECAR↓, 1,   GlucoseCon↑, 2,   Glycolysis↓, 1,   GSK‐3β↓, 1,  

Cell Death(tgid=5) ⓘ

Casp↓, 1,   TumCD↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

p‑Akt↑, 1,   mTOR↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,   other?, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

LC3B↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

cellSen↝, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

neuroG↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 6,   CellMemb↑, 1,   CX43/GJA1↑, 1,   memfluid↑, 1,   MMP↑, 1,   THBD↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL6↓, 1,   Inflam↓, 4,   NeuroI↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

BrainVol↑, 1,   CARTPT↑, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 2,   tau↓, 3,   p‑tau↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 2,   Dose?, 1,   Dose↝, 3,   eff↝, 1,   selectivity↑, 1,   Synergy↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

BloodF↑, 2,   IL6↓, 1,   NOS2↓, 2,  

Functional Outcomes(tgid=23) ⓘ

cognitive↑, 4,   memory↑, 5,   motorD↑, 1,   neuroP↑, 5,   Stroke↓, 3,  

Infection & Microbiome(tgid=24) ⓘ

Sepsis↓, 1,  
Total Targets: 62

Research papers

Year Title Authors PMID Link Flag
2026Methylene blue modulates mitochondrial electron flow via multiple regulatory sites in isolated brain mitochondria: Implications for neurodegenerationZdeněk Fišar42822383https://pubmed.ncbi.nlm.nih.gov/42822383/0
2025Spectroscopic Study of Methylene Blue Interaction with Coenzymes and its Effect on Tumor MetabolismDV PominovaPMC11892571https://pmc.ncbi.nlm.nih.gov/articles/PMC11892571/0
2024Methylene Blue-Mediated Photodynamic Therapy in Combination With Doxorubicin: A Novel Approach in the Treatment of HT-29 Colon Cancer CellsNima Rastegar-PouyaniPMC11822234https://pmc.ncbi.nlm.nih.gov/articles/PMC11822234/0
2024In Vitro Methylene Blue and Carboplatin Combination Triggers Ovarian Cancer Cells DeathJorgelindo da Veiga MoreiraPMC11507203https://pmc.ncbi.nlm.nih.gov/articles/PMC11507203/0
2024The use of methylene blue to control the tumor oxygenation levelDaria Pominova—https://www.sciencedirect.com/science/article/pii/S15721000240008630
2024Methylene blue and its potential in the treatment of traumatic brain injury, brain ischemia, and Alzheimer's diseaseNickolay K Isaev38530227https://pubmed.ncbi.nlm.nih.gov/38530227/0
2023Methylene blue in anticancer photodynamic therapy: systematic review of preclinical studiesAmir TaldaevPMC10568458https://pmc.ncbi.nlm.nih.gov/articles/PMC10568458/0
2023Exploring Methylene Blue and Its Derivatives in Alzheimer's Treatment: A Comprehensive Review of Randomized Control TrialsMuhammad Usman HashmiPMC10631450https://pmc.ncbi.nlm.nih.gov/articles/PMC10631450/0
2022Methylene blue for intractable pain from oral mucositis related to cancer treatment: a randomized phase 2 clinical trialCarlos J RoldanPMC9632023https://pmc.ncbi.nlm.nih.gov/articles/PMC9632023/0
2021The effect of dual-frequency ultrasound waves on B16F10 melanoma cells: Sonodynamic therapy using nanoliposomes containing methylene blueAkbar Adelnia33085810https://pubmed.ncbi.nlm.nih.gov/33085810/0
2020Mitochondria as a target for neuroprotection: role of methylene blue and photobiomodulationLuodan YangPMC7262767https://pmc.ncbi.nlm.nih.gov/articles/PMC7262767/0
2020Methylene blue and its importance in medicineYaren Kayabasi—https://www.researchgate.net/publication/347993459_Methylene_blue_and_its_importance_in_medicine0
2019From Mitochondrial Function to Neuroprotection – An Emerging Role for Methylene BlueDonovan TuckerPMC5826781https://pmc.ncbi.nlm.nih.gov/articles/PMC5826781/0
2018Anticancer activity of methylene blue via inhibition of heat shock protein 70Dhaval Sanchala30257315https://pubmed.ncbi.nlm.nih.gov/30257315/0
2017Methylene blue photodynamic therapy induces selective and massive cell death in human breast cancer cellsAncély F dos SantosPMC5353937https://pmc.ncbi.nlm.nih.gov/articles/PMC5353937/0
2015Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dotsShao-Hua YangPMC4871783https://pmc.ncbi.nlm.nih.gov/articles/PMC4871783/0
2013Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blueJulio C RojasPMC3265679https://pmc.ncbi.nlm.nih.gov/articles/PMC3265679/0
2013Reversing the Warburg Effect as a Treatment for GlioblastomaEthan PoteetPMC3610988https://pmc.ncbi.nlm.nih.gov/articles/PMC3610988/0
2013Methylene blue-mediated photodynamic therapy enhances apoptosis in lung cancer cellsEun Jin Lim23708127https://pubmed.ncbi.nlm.nih.gov/23708127/0
2011Apoptosis of ovarian cancer cells induced by methylene blue-mediated sonodynamic actionJunyan Xiang21147492https://pubmed.ncbi.nlm.nih.gov/21147492/0
2009The sonodynamic antitumor effect of methylene blue on sarcoma180 cells in vitroChiyo Komori19528509https://pubmed.ncbi.nlm.nih.gov/19528509/0
2008High absolute bioavailability of methylene blue given as an aqueous oral formulationIngeborg Walter-Sack18810398https://pubmed.ncbi.nlm.nih.gov/18810398/0
2025Synergistic Neuroprotection in Tauopathic Mice via Green-Synthesized Silver Nanoparticles Co-delivering Methylene Blue and Moringa oleiferaYasmin ElbermawyPMC12743692https://pmc.ncbi.nlm.nih.gov/articles/PMC12743692/0